Clinical Trial Update: Safety Study of Oral BTA9881 to Treat RSV Infection [Phase 1]

View source ↗

Summary

Phase 1 safety study of oral BTA9881 for Respiratory syncytial virus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BTA9881

Snippet

Sponsor: Biota Scientific Management Pty Ltd | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED